| Popis: |
In recent years, monoclonal antibodies have become an important cancer therapeutic modality. Genetically engineered humanized antibodies have demonstrated activity against both minimal residual disease and overt leukemia. High-dose radioimmunotherapy can potentially allow intensification of antileukemic therapy bone marrow transplantation yet minimize radiation exposure to normal organs. Targeted α particle therapy offers the possibility of selective tumor cell kill while sparing surrounding normal cells. Additionally, antibody-drug conjugates such as gemtuzumab ozogamicin have produced responses in acute myelogenous leukemia. |
